Literature DB >> 6323375

Clavulanic acid in combination with ticarcillin: an in-vitro comparison with other beta-lactams.

A M Clarke, S J Zemcov.   

Abstract

The in-vitro activity of ticarcillin in combination with clavulanic acid was compared with that of ticarcillin alone, piperacillin, cefotaxime and, where appropriate, other beta-lactams against a total of 301 recent clinical isolates and characterized beta-lactamase producers. An agar dilution procedure was used to determine MICs and two inocula (10(4) and 10(6) cfu) were used throughout. MICs of the combination of ticarcillin and clavulanic acid were expressed as MICs of ticarcillin in the presence of 5 or 10 mg/l of clavulanic acid. Against most members of the Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia stuartii and Serratia marcescens), ticarcillin plus clavulanic acid was as active as or more active than piperacillin. Against Staphylococcus aureus. Haemophilus influenzae and the Bacteroides fragilis group the combination was considerably more active than piperacillin. Piperacillin was more active than the ticarcillin/clavulanic acid combination against Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323375     DOI: 10.1093/jac/13.2.121

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Discrepancies between disk diffusion and broth susceptibility studies of the activity of ticarcillin plus clavulanic acid against ticarcillin-resistant Pseudomonas aeruginosa.

Authors:  F A Manian; R H Alford
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

2.  Bactericidal effects of ticarcillin-clavulanic acid against beta-lactamase-producing bacteria in vivo.

Authors:  R J Boon; A S Beale; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

4.  Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.

Authors:  K S Thomson; D A Weber; C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 5.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  In vitro activities of enoxacin, ticarcillin plus clavulanic acid, aztreonam, piperacillin, and imipenem and comparison with commonly used antimicrobial agents.

Authors:  D Henry; A G Skidmore; J Ngui-Yen; A Smith; J A Smith
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.